Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,271 signal articles · 38 in last 24h · 115,376 total before filter · latest 1h ago
38last 24h
1778last 7d
298● bullish (7d)
168● bearish (7d)
205publishers
AllMacro314Earnings829M&A103Regulatory25Product16Analyst25
✕ clear all filtersticker: GESentiment:bullishneutralbearish✓ showing all (incl. clickbait)
GE Aerospace Faces Rare Earth Reset As U.S. Rules Tighten
Simply Wall St.107d agoneutral
GE Aerospace Faces Rare Earth Reset As U.S. Rules Tighten

U.S. procurement rules will prohibit Chinese origin rare earth materials in defense applications from January 2027. China currently supplies a large share of global rare earth alloys used in aerospace engines and components. Domestic U.S. rare earth projects are scaling up to supply companies such as GE Aerospace, part of General Electric (NYSE:GE). General Electric (NYSE:GE), trading at $283.57, sits at the center of this supply chain reset through its GE Aerospace business, which depends...

GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip
24/7 Wall St.107d agobearish
GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare (NASDAQ: GEHC) currently trades at $59.49, well below the Wall Street consensus price target of $89.74. That implies upside of roughly 50.8% if the analysts are right. GE HealthCare is the medical imaging and diagnostics business spun from General Electric, with about $20.6 billion in annual revenue across Advanced Imaging Solutions, Patient Care ... GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare Technologies Q1 Earnings Call Highlights
MarketBeat108d agoneutral
GE HealthCare Technologies Q1 Earnings Call Highlights

GE HealthCare Technologies (NASDAQ:GEHC) reported first-quarter 2026 results that management said landed at the high end of expectations on revenue, while profits and cash flow guidance for the full year were reduced to reflect higher input costs and a first-quarter supplier-related recall in Pharma